PMPRB Contact Information:

*Member of Parliament*

Name of Member of Parliament  
House of Commons  
Ottawa, Ontario K1A 0A6

*Minister of Health*

The Honourable Patty Hajdu  
Minister of Health  
House of Commons  
Ottawa, Ontario K1A 0A6 [hcminister.ministresc@canada.ca](mailto:hcminister.ministresc@canada.ca) or [Patty.Hajdu@parl.gc.ca](mailto:Patty.Hajdu@parl.gc.ca)

Letter opener [If sent by postal mail]:  
First and last name  
Title  
Government Department  
Address

Date

Subject line [If sent by email]*:*  
More is needed for metastatic patients like me

Dear Honourable Patty Hadju/Name of Councillor,

My name is Kelly Slynch and I am a mother and new grandmother and I am living with metastatic breast cancer. I am writing today to share my concerns regarding new changes to the Patented Medicines Prices Review Board (PMPRB) regulations and the impact they may have on cancer patients.

[Identify issue] I am concerned that the rapid implementation of these regulations could result in less availability and accessibility to innovative cancer medications in Canada. There is no doubt that medications in Canada should be more affordable for patients.  [Impact of issue] However, some of the proposed changes outlined by the PMPRB could result in fewer therapy options for cancer patients. If Canada proceeds too quickly with implementing these changes, companies may decide to delay or halt drug launches in our country, leaving patients without essential and life-saving therapies available in other parts of the world.

These changes could also potentially impact the accessibility of clinical trials in Canada-which would have devastating consequences for cancer patients. For many cancer patients, clinical trials represent an opportunity to benefit from innovative therapies. This is especially true for patients who have exhausted other treatment options. If global drug manufacturers view Canada as a lower priority or a difficult market to enter, our access to clinical trials may also be compromised.

[Personal story] Now 54 years old, I was diagnosed with metastatic breast cancer (Stage IV) in June 2010. As a mother and a new grandmother, I look forward to spending as much time with my loved ones as possible. And this summer, I’ll be traveling across the U.S. and Canada with my family, visiting iconic landmarks I’ve never seen before – like Niagara Falls. For women like me, a new year brings new hope. New treatments are available to help extend the number of sunrises, road trips, laughs and hugs with family members – an important New Year’s resolution to keep.

[Impact of issue] The proposed PMPRB changes could greatly impact my ability to access medications that prolong my survival.

[Proposed resolution and call-to-action] I urge you to consider the recommendations that were made by the patient community in Canada, including instituting a phased approach to implementation, developing a rigorous monitoring and evaluation process and engaging collaboratively to make patient voices a permanent part of the decision-making process at PMPRB.

With the ongoing COVID-19 pandemic, access to new treatments and vaccines has never been more important. It is essential that our health regulatory systems are able to support access to innovative and life-saving treatments for all Canadians.

Sincerely,

Kelly Slynch  
Vancouver, BC, V5V 5V5

[Insert at least one form of contact if letter is sent via postal mail]